Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 75.0 | 72 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 77.0 | 69 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 86.0 | 68 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 97.0 | 65 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 143.0 | 65 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 148.0 | 53 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 99.5 | 52 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 109.5 | 52 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 155.0 | 55 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 142.0 | 56 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 831.5 | 54 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 199.0 | 51 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 184.0 | 69 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 184.0 | 58 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 1377.0 | 61 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 264.0 | 62 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 230.0 | 55 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | FGF Basic | 217.0 | 61 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 198.0 | 43 | |
N2645 | TNF-a | 100 | ng/mL | 4 | FGF Basic | 214.0 | 49 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 209.0 | 75 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | FGF Basic | 202.0 | 50 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 4 | FGF Basic | 87.5 | 68 | ||||
RA2159 | IKK16 | 2.0 | uM | 4 | FGF Basic | 88.0 | 72 | ||||
N2645 | 5z-7-oxozeaenol | 0.6 | uM | 4 | FGF Basic | 73.0 | 52 |